TMPRSS6 iRNA compositions and methods of use thereof

US10246713B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• James Butler · Lynnfield, US
• Martin Maier · Cambridge, US
• Kevin Fitzgerald · Brookline, US
• Shannon Fishman · Cambridge, US
• Donald C. Foster · Lake Forest Park, US
• Vasant Jadhav · Cambridge, US
• Stuart Milstein · Cambridge, US

Key dates

• Filing date: May 24, 2017
• Grant date: Apr 2, 2019
• Expiry date: May 24, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.